KLRC2: A Potential Drug Target and Biomarker (G3822)

Target Name: KLRC2

NCBI ID: G3822

KLRC2

KLRC2: A Potential Drug Target and Biomarker

Killer cell lectin-like receptor subfamily C, member 2 (KLRC2) is a protein that plays a crucial role in immune surveillance against infections and tumors. Its discovery and functional studies have aroused widespread research interest. This article will discuss the discovery, function, biomarkers and drug targets of KLRC2.

1. Discovery of KLRC2

KLRC2 is a protein located on the short arm of human chromosome 17. Its full length is approximately 220 amino acids and consists of two domains: N-terminal domain and C-terminal domain. The N-terminal domain includes an N-terminal 伪-helix, an N-terminal 尾-sheet, and an N-terminal hydrophobic domain. The C-terminal domain includes a C-terminal 伪-helix, a C-terminal 尾-sheet, and a C-terminal hydrophobic domain. The link between the two domains is a 尾-coil consisting of a long sequence of amino acids.

2. Functions of KLRC2

KLRC2 plays an important role in immune response. It is an important immune cell recognition receptor that can bind foreign bodies such as pathogens, cell debris, and tumor cells. By recognizing these foreign bodies, KLRC2 activates immune cells and triggers specific immune responses to protect the body from infection and tumor threats.

The role of KLRC2 in immune surveillance is mainly reflected in tumor immune escape. Tumor cells are often able to evade immune surveillance in a variety of ways, including by downregulating the expression level of KLRC2, inhibiting the interaction between KLRC2 and ligands, and changing the intracellular localization of KLRC2. However, researchers have found that the expression level of KLRC2 is significantly increased in a variety of tumors, and KLRC2-specific drugs can significantly inhibit tumor growth and metastasis. These results indicate that KLRC2 may be a potential therapeutic target for tumor immune evasion.

3. Biomarkers of KLRC2

Due to the important role of KLRC2 in tumor immune evasion, studying KLRC2 biomarkers has important clinical significance for tumor immunotherapy. At present, some biomarkers related to KLRC2 have been discovered, including KLRC2 antibodies, KLRC2 mRNA and KLRC2 protein.

KLRC2 antibody is an immunoglobulin that can bind to KLRC2 and can be used to detect the expression level and function of KLRC2. KLRC2 mRNA and KLRC2 protein can be used to evaluate the expression level of KLRC2 and the efficacy of KLRC2 blocking drugs. These biomarkers are of great significance for studying the mechanism of action of KLRC2, drug screening and tumor immunotherapy.

4. Drug targets of KLRC2

The important role of KLRC2 in tumor immune evasion makes it an important drug target. Some drugs that inhibit KLRC2 expression have entered clinical research, including anti-KLRC2 antibodies, KLRC2-specific drugs, and KLRC2 antagonists.

Anti-KLRC2 antibody is an immunoglobulin that can bind to KLRC2 and can be used to detect the expression level and function of KLRC2. KLRC2-specific drugs are drugs that can specifically bind to KLRC2 and can be used to inhibit the expression of KLRC2 in tumor cells. KLRC2 antagonists are drugs that block the binding of KLRC2 to ligands and can be used to treat KLRC2-positive tumors.

In summary, KLRC2 is an important immune cell recognition receptor and plays an important role in tumor immune escape. Biomarkers such as KLRC2 antibodies, KLRC2 mRNA and KLRC2 protein are of great significance for studying the mechanism of action of KLRC2, drug screening and tumor immunotherapy. At the same time, KLRC2 is also regarded as an important drug target, and drugs such as anti-KLRC2 antibodies, KLRC2-specific drugs, and KLRC2 antagonists have entered clinical research.

Protein Name: Killer Cell Lectin Like Receptor C2

Functions: Immune activating receptor involved in self-nonself discrimination. In complex with KLRD1 on cytotoxic lymphocyte subsets, recognizes non-classical major histocompatibility (MHC) class Ib HLA-E loaded with signal sequence-derived peptides from non-classical MHC class Ib HLA-G molecules, likely playing a role in the generation and effector functions of adaptive natural killer (NK) cells and in maternal-fetal tolerance during pregnancy (PubMed:9754572, PubMed:30134159). Regulates the effector functions of terminally differentiated cytotoxic lymphocyte subsets, and in particular may play a role in adaptive NK cell response to viral infection (PubMed:21825173, PubMed:20952657). Upon HLA-E-peptide binding, transmits intracellular signals via the adapter protein TYROBP/DAP12, triggering the phosphorylation of proximal signaling molecules and cell activation (PubMed:9655483, PubMed:15940674)

The "KLRC2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KLRC2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets